Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Kimberly R. Lindsey(National Cancer Institute), Suzanne L. Topalian(Bloomberg (United States)), Seth M. Steinberg(National Institutes of Health), Lisa C. Goldfeder(National Institute of Allergy and Infectious Diseases), Sharon Mavroukakis(Stanford Medicine), Patricia Fetsch(National Institutes of Health), Dennis Panicali(Fox Chase Cancer Center), Steven A. Rosenberg(National Cancer Institute), Linda Gritz, Nicholas P. Restifo(Lyell Immunopharma (United States)), Richard M. Sherry(Unknown), Linda Rogers-Freezer, Donald E. White(National Institutes of Health), Monica I. Gonzales(National Cancer Institute), Leah Haworth(National Cancer Institute), Andrea Abati(National Institutes of Health), Kimberly Zinnack
Cited by 50
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k